Here is what I had scrawled down on
that--I think this is not new news:
In original trials 15-20% of patients
had a "dramatic" response...meaning
greater than a 50% reduction in tumors.
There is a mart-1/gp100 (my notes are
not very good here) phase I/II ongoing
which is "in the middle of the trial"
and "results are coming next year".
You could obviously snag that off the replay
as well. Where I was most impressed with Gail
was listening in on the conversations between
presentations.
Oh, here is something I scrawled down for Rick:
The slide with the small molecules...
Anti-Angiogenesis>
Proteins, Gene Therapy, Small Molecules...
and under small molecules>>
Growth Factors, Extracellular matrix, Cell Proliferation
--and all that was listed as "research stage"
When I asked about patenting transcripts found with
SAGE I got the expected answer--sorry, no easter eggs,
and you can get that off the replay as well.
Oh, she might also said something about not worrying
so much about the quarterly financials...and that cash
is good through 2001--the fellow from Corixa made that
point as well, and Parker from TGEN--they all want to
keep investors calm about that little cash item that
everybody seems to sweat, some quarters just burn a
lot more than others. |
